戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (right1)

通し番号をクリックするとPubMedの該当ページを表示します
1  AFL-assisted powder reservoir patch delivery showed a good safety.
2               However, few data support its feasibility and safety.
3 val, event-free survival, and progression-free survival and safety.
4 r importance for society and future improvements in nuclear safety.
5 uate to ensure surgeon proficiency and may threaten patient safety.
6 ritical to our understanding of this potential risk to food safety.
7                                                     Overall safety and activity of liso-cel did not differ by dose level.
8 istication of immune cell therapies, increasing potency and safety and broadening their potential for treatment of diseas
9                                                         The safety and effectiveness of dual therapy (direct oral anticoa
10              The aim of this study was to provide long-term safety and efficacy data for evolocumab in patients with homo
11 te to provide sustained-release of GRFT, and to examine its safety and efficacy in a murine model of lethal HSV-2 infecti
12                                    Our understanding of the safety and efficacy of cannabis has been limited by decades o
13 ified randomized controlled trials (RCTs) investigating the safety and efficacy of systemic treatments for AD up to Febru
14                                       We sought to evaluate safety and efficacy of the JAK1/2 inhibitor ruxolitinib in pa
15 D-19 vaccine development and our approach to optimizing for safety and efficacy.
16                                    A detailed assessment of safety and tolerability of the study drugs was done in all pa
17                                    The primary endpoint was safety and we observed 6 of 28 patients (21%) with grade >=3
18                        The primary outcome of the study was safety, and secondary outcomes included visual acuity, microp
19                      Our aim was to determine the efficacy, safety, and tolerability of berotralstat in patients with HAE
20 3 phase-3 randomized clinical trials (AMAGINE -1 [Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab in Mod
21 cases of symptomatic, virologically confirmed COVID-19, and safety, as measured by the occurrence of serious adverse even
22  data and BCAR episodes from all six CTG trials revealed no safety concerns when compared with the RGT.
23 nd will be outlined in brief, as well as an introduction to safety designations and nomenclature put forth by the America
24 -quality scans and evaluated the diagnostic performance and safety in a phase III study of patients with SSTR-expressing
25  Monitoring before and during therapy for effectiveness and safety is recommended.
26 ppb lead, 10 ppb bisphenol A, and 1 ppb paraoxon, tested as safety limits.
27  Moderate to Severe Plaque Psoriasis], and -3 [Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in
28                      In the United States, the efficacy and safety of convalescent plasma for treating coronavirus diseas
29                        We aimed to measure the efficacy and safety of gabapentin in women with chronic pelvic pain and no
30           The phase 3 ASPEN study compared the efficacy and safety of ibrutinib, a first-generation BTK inhibitor, with z
31 nfirm results on long-term outcome focusing on efficacy and safety of long-term use of rituximab maintenance.
32 nd larger trials are necessary to evaluate the efficacy and safety of sodium phenylbutyrate-taurursodiol in persons with
33                      The Observational Study of the Use and Safety of Xolair (omalizumab) during Pregnancy (EXPECT) pregn
34   Because both diets reduced urinary sodium without adverse safety or quality of life signals, a larger trial, with modif
35                   Systematic collation of certain important safety outcomes was rare.
36              Secondary end points included angiographic and safety outcomes.
37 The secondary endpoints analysed within this report include safety, overall survival, and duration of response, in keepin
38 tial attention from scientists for the advantages of better safety performance.
39                   At Week 48, DOR at 100 mg had a favorable safety profile compared with EFV or DRV+r and a favorable tol
40 rutinib is active as single-agent therapy with a manageable safety profile in patients with treatment-naive, or relapse o
41  and robotic ablation allows PV isolation with good chronic safety; PV isolation success is improving with device enhance
42  postmarketing reports, and assessments from an independent Safety Review Committee (SRC); and (3) their clinical experie
43 ded in the per protocol analysis, and 20 071 (99.9%) in the safety set.
44 ed, double-blind, placebo-controlled study investigated the safety, tolerability, and pharmacokinetics of nilotinib, and
45 he effect of high-dose intravenous immunoglobulin (IVIg) on safety, tolerability, pharmacokinetics (PK), and pharmacodyna
46                                                             Safety was assessed in all participants who received at least
47                                                             Safety was assessed in all patients who received at least one
48                                                             Safety was assessed up to 48 h post-injection.
49 etal batteries with a simple battery configuration and high safety, which is different from traditional molten-salt Li me
50 at the brolucizumab q12-week regimen maintains efficacy and safety while reducing treatment burden associated with regula